This inventor holds 2 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: National Institute of Health and Medical Research, The University of Nantes, Centre National De La Recherche Scientifique. Active years: 2017-2024.
Company Filing History:
2 out of 1,853 
2 out of 156 
1 out of 5,383 
Years Active: 2017-2024
Title: François Lang: Innovator in Melanoma Treatment
Introduction
François Lang is a notable inventor based in Nantes, France. He has made significant contributions to the field of medical research, particularly in the prevention and treatment of diseases such as cancer. With a total of 2 patents, his work focuses on innovative strategies to enhance immune responses against melanoma.
Latest Patents
Lang's latest patents include a groundbreaking approach to vaccination strategies. One of his inventions relates to a synthetic long peptide (SLP) that comprises a CD4 class II peptide linked to a CD8 class I peptide. This invention aims to stimulate T cell activation and proliferation, which is crucial for effective cancer treatment. Another patent involves a melanoma antigen peptide that includes specific amino acid sequences designed for the prevention and treatment of melanoma in patients. These inventions highlight his commitment to advancing cancer therapies through innovative methodologies.
Career Highlights
Throughout his career, François Lang has worked with esteemed institutions such as the National Institute of Health and Medical Research (Institut National De La Santé Et De La Recherche Médicale) and the University of Nantes (Université De Nantes). His research has been pivotal in understanding the immune mechanisms involved in melanoma and developing effective therapeutic strategies.
Collaborations
Lang has collaborated with notable colleagues, including Nathalie Labarriere and Mathilde Bobinet. These partnerships have enriched his research and contributed to the advancement of cancer treatment methodologies.
Conclusion
François Lang's innovative work in the field of melanoma treatment exemplifies the impact of dedicated research on public health. His patents and collaborations reflect a commitment to improving cancer therapies and enhancing patient outcomes.